Scroll

nimodipine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
calcium channel blockers, nifedipine derivatives	1937	66085-59-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nimodipine nemotan nymalize	A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure. Molecular weight: 418.45 Formula: C21H26N2O7 CLOGP: 4 LIPINSKI: 0 HAC: 9 HDO: 1 TPSA: 117 ALOGS: -4.54 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nimodipine
nemotan
nymalize

A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.

Molecular weight: 418.45
Formula: C21H26N2O7
CLOGP: 4
LIPINSKI: 0
HAC: 9
HDO: 1
TPSA: 117
ALOGS: -4.54
ROTB: 10

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.30	g	O
50	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	14.34 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	11 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.10 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	15 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 28, 1988	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Patent ductus arteriosus	80.95	35.10	17	793	4233	63483979
Subarachnoid haemorrhage	65.05	35.10	18	792	14265	63473947
Reversible cerebral vasoconstriction syndrome	58.55	35.10	12	798	2646	63485566
Premature baby	41.95	35.10	14	796	20721	63467491
Mixed liver injury	36.14	35.10	9	801	4726	63483486
Foetal exposure during pregnancy	36.03	35.10	14	796	31948	63456264
Cerebral vasoconstriction	35.88	35.10	7	803	1201	63487011

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Brain injury	84.27	64.44	20	613	6122	34950176
Cerebral ischaemia	78.52	64.44	19	614	6303	34949995
Intensive care unit acquired weakness	65.77	64.44	12	621	1015	34955283
Sinus bradycardia	65.00	64.44	19	614	12944	34943354

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral ischaemia	86.62	34.40	23	1395	11172	79731798
Subarachnoid haemorrhage	72.88	34.40	24	1394	24441	79718529
Brain injury	71.97	34.40	20	1398	11497	79731473
Mixed liver injury	70.35	34.40	18	1400	7560	79735410
Cardiogenic shock	60.27	34.40	24	1394	41890	79701080
Intensive care unit acquired weakness	58.35	34.40	12	1406	1921	79741049
Reversible cerebral vasoconstriction syndrome	58.32	34.40	13	1405	3044	79739926
Alcohol abuse	56.01	34.40	14	1404	5349	79737621
Sinus bradycardia	52.73	34.40	19	1399	25228	79717742
Polyneuropathy	49.78	34.40	18	1400	24133	79718837
Cerebral vasoconstriction	49.53	34.40	10	1408	1460	79741510
Thunderclap headache	48.13	34.40	8	1410	397	79742573
Hyperlactacidaemia	40.90	34.40	11	1407	5584	79737386
Alcohol use disorder	40.11	34.40	5	1413	29	79742941
Lactic acidosis	39.62	34.40	21	1397	70338	79672632
Behaviour disorder	39.59	34.40	11	1407	6302	79736668
Hypotension	38.51	34.40	43	1375	440274	79302696
Cognitive disorder	36.93	34.40	20	1398	69906	79673064
Cardiovascular disorder	35.51	34.40	13	1405	18012	79724958
Impaired work ability	34.40	34.40	13	1405	19668	79723302

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C08CA06	CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives
FDA CS	M0006414	Dihydropyridines
FDA MoA	N0000000069	Calcium Channel Antagonists
FDA EPC	N0000175421	Dihydropyridine Calcium Channel Blocker
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002121	Calcium Channel Blockers
MeSH PA	D000077264	Calcium-Regulating Hormones and Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D014665	Vasodilator Agents
CHEBI has role	CHEBI:35554	cardiovascular agent
CHEBI has role	CHEBI:35620	vasodilator agents
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:38215	calcium channel blockers

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Subarachnoid intracranial hemorrhage	indication	21454007
nerve regeneration after iatrogenic nerve injury	off-label use	57182000
Essential tremor	off-label use	609558009	DOID:4990
Low blood pressure	contraindication	45007003
Chronic idiopathic constipation	contraindication	82934008
Disease of liver	contraindication	235856003	DOID:409

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.09	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
6MG/ML	NYMALIZE	AZURITY	N203340	April 8, 2020	RX	SOLUTION	ORAL	10342787	April 16, 2038	A METHOD FOR THE IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE (SAH) FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS
6MG/ML	NYMALIZE	AZURITY	N203340	April 8, 2020	RX	SOLUTION	ORAL	10576070	April 16, 2038	A METHOD FOR THE IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE (SAH) FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS
6MG/ML	NYMALIZE	AZURITY	N203340	April 8, 2020	RX	SOLUTION	ORAL	11207306	April 16, 2038	A METHOD FOR THE IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE (SAH) FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS
6MG/ML	NYMALIZE	AZURITY	N203340	April 8, 2020	RX	SOLUTION	ORAL	11413277	April 16, 2038	A METHOD FOR THE IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE (SAH) FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Voltage-dependent L-type calcium channel subunit alpha-1C	Ion channel	Q13936	CAC1C_HUMAN	BLOCKER			UNKNOWN	CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1D	Ion channel	Q01668	CAC1D_HUMAN	BLOCKER			UNKNOWN	CHEMBL
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		Ki	6.12	WOMBAT-PK
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.07	WOMBAT-PK
Nuclear receptor subfamily 1 group I member 2	Nuclear hormone receptor	O75469	NR1I2_HUMAN		EC50	6.41	CHEMBL
Voltage-dependent calcium channel gamma-1 subunit	Ion channel	Q06432	CCG1_HUMAN				WOMBAT-PK
Mineralocorticoid receptor	Nuclear hormone receptor	P08235	MCR_HUMAN	ANTAGONIST	IC50	6.80	IUPHAR
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	4.86	CHEMBL
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	6	DRUG MATRIX
Voltage-dependent T-type calcium channel subunit alpha-1H	Ion channel	O95180	CAC1H_HUMAN		Ki	5.25	WOMBAT-PK
Voltage-dependent L-type calcium channel subunit alpha-1S	Ion channel	Q13698	CAC1S_HUMAN	GATING INHIBITOR	IC50	6	IUPHAR
Cytochrome P450 2C19	Enzyme	P33261	CP2CJ_HUMAN		IC50	5.40	DRUG MATRIX
cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Enzyme	Q08499	PDE4D_HUMAN		IC50	5.15	CHEMBL
Bile acid receptor	Nuclear hormone receptor	Q96RI1	NR1H4_HUMAN		IC50	5.05	CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1F	Ion channel	O60840	CAC1F_HUMAN	GATING INHIBITOR	IC50	6	IUPHAR
Sodium/nucleoside cotransporter 1	Transporter	O00337	S28A1_HUMAN		Ki	6.36	DRUG MATRIX
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Enzyme	Q14123	PDE1C_HUMAN		IC50	5.91	CHEMBL
Cannabinoid receptor 1	GPCR	P21554	CNR1_HUMAN		Ki	5.86	DRUG MATRIX
Adenosine receptor A1	GPCR		AA1R_RAT		Ki	4.70	CHEMBL
Adenosine receptor A2a	GPCR		AA2AR_RAT		Ki	4.35	CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C	Ion channel		CAC1C_RAT	GATING INHIBITOR	IC50	6.80	IUPHAR
Voltage-dependent L-type calcium channel subunit alpha-1D	Ion channel		CAC1D_RAT	GATING INHIBITOR	IC50	6.60	IUPHAR

External reference:

ID	Source
4019390	VUID
N0000147543	NUI
D00438	KEGG_DRUG
4019390	VANDF
C0028094	UMLSCUI
CHEBI:7575	CHEBI
6U9	PDB_CHEM_ID
CHEMBL255033	ChEMBL_ID
CHEMBL1428	ChEMBL_ID
D009553	MESH_DESCRIPTOR_UI
DB00393	DRUGBANK_ID
4497	PUBCHEM_CID
2523	IUPHAR_LIGAND_ID
4528	INN_ID
57WA9QZ5WH	UNII
1423768	RXNORM
109672	MMSL
203915	MMSL
5177	MMSL
d00318	MMSL
000713	NDDF
387502003	SNOMEDCT_US
87285001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Nimodipine	HUMAN PRESCRIPTION DRUG LABEL	1	23155-512	CAPSULE, LIQUID FILLED	30 mg	ORAL	ANDA	13 sections
Nimodipine	HUMAN PRESCRIPTION DRUG LABEL	1	23155-512	CAPSULE, LIQUID FILLED	30 mg	ORAL	ANDA	13 sections
Nymalize	HUMAN PRESCRIPTION DRUG LABEL	1	24338-200	SOLUTION	60 mg	ORAL	NDA	25 sections
Nymalize	HUMAN PRESCRIPTION DRUG LABEL	1	24338-205	SOLUTION	30 mg	ORAL	NDA	25 sections
Nymalize	HUMAN PRESCRIPTION DRUG LABEL	1	24338-230	SOLUTION	30 mg	ORAL	NDA	26 sections
Nymalize	HUMAN PRESCRIPTION DRUG LABEL	1	24338-230	SOLUTION	30 mg	ORAL	NDA	26 sections
Nymalize	HUMAN PRESCRIPTION DRUG LABEL	1	24338-260	SOLUTION	60 mg	ORAL	NDA	26 sections
Nymalize	HUMAN PRESCRIPTION DRUG LABEL	1	24338-260	SOLUTION	60 mg	ORAL	NDA	26 sections
Nimodipine	HUMAN PRESCRIPTION DRUG LABEL	1	62559-210	CAPSULE	30 mg	ORAL	ANDA	23 sections
Nimodipine	HUMAN PRESCRIPTION DRUG LABEL	1	63739-797	CAPSULE, LIQUID FILLED	30 mg	ORAL	ANDA	25 sections
Nimodipine	HUMAN PRESCRIPTION DRUG LABEL	1	67877-297	CAPSULE, LIQUID FILLED	30 mg	ORAL	ANDA	26 sections
Nimodipine	HUMAN PRESCRIPTION DRUG LABEL	1	68084-912	CAPSULE, LIQUID FILLED	30 mg	ORAL	ANDA	26 sections
Nimodipine	HUMAN PRESCRIPTION DRUG LABEL	1	68084-912	CAPSULE, LIQUID FILLED	30 mg	ORAL	ANDA	26 sections
Nimodipine	HUMAN PRESCRIPTION DRUG LABEL	1	68084-912	CAPSULE, LIQUID FILLED	30 mg	ORAL	ANDA	26 sections
Nimodipine	HUMAN PRESCRIPTION DRUG LABEL	1	69452-209	CAPSULE, LIQUID FILLED	30 mg	ORAL	ANDA	23 sections